“Why on God’s earth not try Leronlimab that is already demonstrating strong immunomodulatory effects in-vivo with demonstrated clinical improvement??”

CYDY was invited to discuss leronlimab with OWS AND CYDY is sitting on a complete it near completed BARDA packet. These two avenues could’ve provided an opportunity to make the NIH more aware of leronlimab’s potential.

Also remember that NP doesn’t work well with others and turned down at least one trial to combine remdesevir with leronlimab. There’s a possibility that he turned down an opportunity to be considered as a molecule for this trial.